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Abstract
Background: The objective of this study was to investigate whether the 13C-phenylalanine breath test could be useful 
for the evaluation of hepatic function in elderly volunteers and patients with chronic hepatitis B and liver cirrhosis.
Methods: L-[1-13C] phenylalanine was administered orally at a dose of 100 mg to 55 elderly patients with liver cirrhosis, 
30 patients with chronic hepatitis B and 38 elderly healthy subjects. The breath test was performed at 8 different time 
points (0, 10, 20, 30, 45, 60, 90, 120 min) to obtain the values of Delta over baseline, percentage 13CO2 exhalation rate 
and cumulative excretion (Cum). The relationships of the cumulative excretion with the 13C-%dose/h and blood 
biochemical parameters were investigated.
Results: The 13C-%dose/h at 20 min and 30 min combined with the cumulative excretion at 60 min and 120 min 
correlated with hepatic function tests, serum albumin, hemoglobin, platelet and Child-Pugh score. Prothrombin time, 
total and direct bilirubin were significantly increased, while serum albumin, hemoglobin and platelet, the cumulative 
excretion at 60 min and 120 min values decreased by degrees of intensity of the disease in Child-Pugh A, B, and C 
patients (P < 0.01).
Conclusions: The 13C-phenylalanine breath test can be used as a non-invasive assay to evaluate hepatic function in 
elderly patients with liver cirrhosis. The 13C-%dose/h at 20 min, at 30 min and cumulative excretion at 60 min may be 
the key value for determination at a single time-point. 13C-phenylalanine breath test is safe and helpful in 
distinguishing different stages of hepatic dysfunction for elderly cirrhosis patients.
Background
The liver plays a key role in major metabolic activities and
breakdown of many drugs and toxins. The ability to eval-
uate its functional mass is a very important parameter .
Function tests in hepatology should provide accurate
information about diagnosis, severity estimation, progno-
sis assessment and therapy evaluation in patients with
liver disease [1]. To improve the conventional static bio-
chemical liver tests (such as ALT, AST, bilirubin, ALP and
ALB levels or PT), several dynamic tests have been pro-
posed over recent decades [2,3]. When it comes to the
liver metabolic function, the appearance of 13CO2  in
breath after 13C-substrate administration means that the
administered substance has undergone liver oxidation,
thus reflecting the cellular function investigated
(microsomal, cytosolic, mitochondrial). 13CO2 breath test
is a simple clinical method for quantifying liver function
and is only based on hepatic oxidation of a 13C-labeled
tracer. As a liver breath test substrate, L-[1-13C] phenyla-
lanine is converted to L-[1-13C] tyrosine and hidroxylated
exclusively in the liver. So L-[1-13C] phenylalanine breath
test (PheBT) is an easy performed functional liver test
that measures cytosolic activity and is independent of
hepatic blood flow. Because impaired liver function may
limit phenylalanine catabolism, and thereby 13CO2 pro-
duction, reduced 13CO2 release in the exhaled breath is
used as an indicator for a disturbed phenylalanine oxida-
tion [4-13]. The basis of PheBT to quantify liver function
is that 13CO2 recovery reflects phenylalanine oxidation
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within the liver and a reduced oxidation might be used as
a marker for hepatocellular dysfunction [14]. Our study
also demonstrated that the PheBT can be used as a non-
invasive assay to evaluate hepatic function in patients
with liver cirrhosis and minimal hepatic encephalopathy
[15]. However, age-related reductions in liver weight, vol-
u m e  a n d  b l o o d  fl o w  h a v e  b e e n  r e p o r t e d ,  a s  w e l l  a s  a
decrease in the number of hepatocytes, changes in hepa-
tocellular structural and functional parameters [16-18].
The purpose of this study is to investigate whether the
13C-phenylalanine breath test could be useful for the eval-
uation of hepatic function in elderly volunteers and
patients with chronic hepatitis B and liver cirrhosis.
Methods
Patients
All the study subjects underwent a complete history and
physical examination, and were > 65 and < 85 years of
age. The patients gave their informed consent to partici-
pate in the study after a full explanation. Diagnosis of
chronic hepatitis B and cirrhosis was made according to
the criteria revised in 2005 National Symposium in China
[19,20]. The diagnosis of chronic HBV was based on the
presence of hepatitis B surface antigen at least 6 months,
elevated serum alanine aminotransferase(ALT) levels,
HBeAg or anti-HBe positive, with or without HBV DNA
as detected by the hybridization method. The diagnosis
of cirrhosis was based on clinical findings, laboratory
tests, imaging studies, and/or liver histological examina-
tion. The cause of liver cirrhosis in patients enrolled in
this study was due to Hepatitis B Virus. All patients were
classified by the Child-Pugh classification, comprising of
ascites, encephalopathy, serum albumin, bilirubin levels
and prothrombin time. The Child-Pugh's scores were
used to assess the severity of liver cirrhosis.
Exclusion criteria were overt hepatic encephalopathy
(HE) or a history of overt HE or neurological or mental
diseases; alcohol liver disease or history of recent (<4
weeks) alcohol intake; history of recent (<4 weeks) use of
drugs affecting psychometric performances like sedative
or other psychotropic drugs and antiviral treatment on
chronic hepatitis B; a history of liver transplantation or
shunt surgery or transjugular intrahepatic portosystemic
shunt for portal hypertension; a history of recent (<4
weeks) gastrointestinal bleeding and electrolyte imbal-
ance; severe medical problems such as congestive heart
failure, pulmonary disease, cerebrovascular diseases, dia-
betes mellitus that could influence breath test. In addi-
tion, the patients who took drugs which could possibly
alter breath tests results (Corticosteroids, Cimetidine,
Diazepam, Omeprazole etc.), patients with thyroid dis-
ease, or fever , were excluded; as were patients with any
digestive disease which could cause malabsortion.
This study was approved by the hospital ethics commit-
tee. Enrollment started September 2006 and ended Janu-
ary 2009, in Huadong Hospital and Renji Hospital. Thirty
elderly patients with a diagnosis of chronic hepatitis B
and 55 elderly patients with a diagnosis of cirrhosis, con-
firmed by clinical findings, laboratory tests, imaging
studies, and, in this study, 3 patients underwent liver his-
tological examination, were invited to take part in the
study. Blood for standard liver tests (serum values of pro-
thrombin time, albumin, total bilirubin, AST, ALT and
alkaline phosphatase) was withdrawn immediately before
performing the breath test.
Comparison Groups
A total of 38 elderly healthy volunteers were included as
control subjects. Thirty-eight healthy volunteers pre-
sented for their yearly physical examinations and had no
specific complaints or illness requiring treatment. None
of them had a history of liver, respiratory or gastrointesti-
nal malabsortion diseases, neither were they receiving
any medication at the time of the study. Biochemical
hepatic function, prothrombin time and platelet count
were normal in all subjects. Before the study, these sub-
jects were on a normal diet and consumed no drugs for
two weeks prior to the test which could affect hepatic
enzyme activity.
Phenylalanine breath test
L-[1-13C] phenylalanine (99% in purity, Isotec, USA) was
administered orally to the subjects at a dose of 100 mg
dissolved in 100 ml of purified water, in the early morn-
ing, in the fasting state, 8 h before the PheBT, while the
patients were at rest in the sitting position. A 10-ml
breath collection tube was used to collect exhaled air.
Exhaled air samples were collected in commercially avail-
able vacutainer tubes, and the straw method before the
drug administration and 10, 20, 30, 45, 60, 90, 120 min
after the isotope administration. The value of 13CO2 in
the exhaled air was determined with an air isotope ratio
mass spectrometer (Analytical Precision Products, Finni-
gan, Germany). The ability of the liver to oxidize phenyla-
lanine at each time-point (%13C dose h-1) was calculated
from the level of 13CO2 in the expired air, on the assump-
tion, based on a report by Schneider et al. that 300 mmol
of CO2 per m2 of body surface area is generated per unit
hour [21]. The cumulative excretion during the 120-min
period following the isotope administration was calcu-
lated by the integration of the excretion rate curve with
time.
Statistical Analysis
All data were analyzed using SPSS (version 15.0; SPSS,
Inc., Chicago, IL). One-way anova by Scheffe's F-test was
used for comparison among multiple groups. Correla-Zhang et al. BMC Geriatrics 2010, 10:23
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tions with the blood biochemical parameters and param-
e t e r s  o f  s c i n t i g r a p h y  w e r e  a s s e s s e d  b y  d e t e r m i n i n g
Pearson's correlation coefficient and Spearman's correla-
tion coefficient. Multiple regression analysis was per-
formed to assess the combined influence of variables on
cumulative excretion, 13C dose at 20 and 30 min. Inter-
group differences were evaluated by the log-rank test.
Data were expressed as mean ± SD. P value less than 0.05
was considered statistically significant.
Results
The age range of all the subjects in our study was 66-84
years. All the 30 patients with chronic hepatitis B and 55
patients with liver cirrhosis and the 38 healthy volunteers
approached for the study, completed 13C-PheBT. The
main demographic and clinical data of samples are shown
in Table 1. The reason for cirrhosis in patients enrolled in
this study was chronic hepatitis B.
Comparison of liver function and blood test in every group
Comparison of liver function and blood test in every
group is shown in Table 2. Compared with healthy con-
trols, patients with chronic hepatitis B and cirrhosis had
worse biochemical parameters, and increasing severity of
liver cirrhosis was associated with significantly decreased
in serum albumin (ALB), haemoglobin (HB) and platelet
count (PLT), and significantly increased in serum total
bilirubin (TBIL) and prothrombin time (PT) (P < 0.05).
Comparison of %13C dose h-1 curves and %13C cumulative 
excretion curves after oral administration of L-[1-13C] 
Phenylalanine in every group
The %13C dose h-1 at 20 min and %13C dose h-1 at 30 min
combined with the cumulative excretion at 60 min and
120 min showed correlations with the chronic liver dis-
eases, especially Child-Pugh score (Table 3, Figure 1A
and 1B). The cumulative excretion at 60 min and 120 min
values decreased by degrees of intensity of the disease in
healthy controls and Child-Pugh A, B, and C patients (P <
0.01).
More 13CO2 was exhaled by healthy subjects than by
those with disease and, in healthy controls, 13CO2
peaked at 20-30 min after the administration of the study
drugs. Cumulative measurements were also investigated
and offered no benefit over single measurements at 60
min. Cumulative excretion should combine with the
%13C dose h-1 at 20 min and %13C dose h-1 at 30 min for
application.
Coefficients of Correlation between PheBT Results and 
Blood Biochemical Parameters
Table 4 shows the correlation between the %13C dose h-1
at 20, 30 min and %13C cumulative excretion at 60, 120
min (the most important parameters) and biochemical
liver function tests. ALB, HB, TBIL, DBIL, PT, PLT and
Child-Pugh score were highly correlated with the
13CO2ER 20, 13CO2ER 30 and 13CCUM 60.
The safety of 13C-PheBT
No side effects such as abdominal pain, abdominal swell-
ing and other signs were observed in any volunteer or
patient, hepatic and renal functions did not significantly
change after oral intake of L-[1-13C] phenylalanine.
Discussion
Quantitative evaluation of hepatocellular function is
important from the aspect of mortality prediction follow-
ing surgery for liver cirrhosis and from that of the prog-
nosis in cases of acute hepatitis. Although several
methods have been used to quantitatively evaluate the
reserve capacity of the liver, e.g. methods evaluating
clearance of galactose and indocianine, ascialoglycopro-
tein receptor of the liver, and breath tests, no definitive
method has been established as yet. Some possible rea-
sons for the difficulty of establishing a definitive method
for the evaluation of liver function are absence of any
entirely safe substrates, the complexity of the tests, and
the invasiveness of the methods. In this regard, breath
tests are safe and non-invasive as a stable isotope is used
as a tracer and simple collection of expired air samples
allows the determination.
Phenylalanine is one of the eight essential amino acids
for humans and must be obtained from dietary sources.
This amino acid is mainly decomposed in the liver, but
with a low extraction from plasma into the liver (E = 0.2),
that is even lower in patients with liver diseases [22-25].
Therefore, as a breath test substrate, phenylalanine pro-
vides a good index of hepatic metabolic capacity. Further-
Table 1: Demographic and Clinical Data of Samples (mean ± SD).
Control Subjects (n = 38) Chronic hepatitis B (n = 30) Cirrhosis (n = 55)
Age 74.1 ± 5.9 74.0 ± 5.3 72.8 ± 5.1
Gender M/F 26/12 21/9 36/19
Height (cm) 164.9 ± 7.8 166.7 ± 7.9 163.5 ± 8.0
Weight (kg) 66.7 ± 9.8 65.3 ± 10.3 62.7 ± 10.2
Child-Pugh Class - - A 19/B 28/C 8Zhang et al. BMC Geriatrics 2010, 10:23
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more, phenylalanine has the additional benefits that its
metabolism is largely unaffected by blood flow rearrange-
ment and it has neither pharmacological nor allergic
properties. These properties make 13C-phenylalanine an
ideal breath test substrate to assess liver function [1].
Phenylalanine oxidation, including hydroxylation to
tyrosine and further degradation, occurs in the hepatic
cytosol. During degradation, the position 1 carbon of
phenylalanine is decarboxylated, with the production of
CO2, which is released in the breath. In the case of L-[1-
13C] phenylalanine being used, 13CO2 is detected as the
final metabolite in the breath.
Burke et al [4] was the first to utilize PheBT to deter-
mine the hepatocyte functional capacity in patients with
end-stage liver diseases. They found that 13CO2 excretion
decreased by up to 80% after intake of L-[1-13C] phenyla-
lanine. In recent years, similar results were subsequently
obtained in different populations [5-13], including our
study [15], however, seldom in elderly populations [26].
Additional estimation of phenylalanine hydroxylase activ-
ity by the 13C-PheBT might be useful in that it evaluates
the real-time condition in patients.
Results emerging from the present study show that
PheBT could discriminate liver function not only
between healthy subjects and liver disease patients, but
also between different stages of cirrhosis patients. Based
on the reference [4-13,27], we selected 8 different time
point to collect exhaled air. The %13C dose h-1 curves
showed the peaks were obvious in group normal and
chronic hepatitis B, and the peak appeared at 10-30 min
after phenylalanine administration, whereas, the curves
decreased along with the severity of liver disease in group
cirrhosis. The %13C dose h-1 at 20 min and 30 min com-
bined with the cumulative excretion at 60 min and 120
min showed correlations with serum albumin, hemoglo-
bin, platelet, prothrombin time, total and direct bilirubin
and Child-Pugh score. With comprehensive analysis of
the results, the exhaled air samples might be only col-
lected at 5 different time point (before the drug adminis-
tration and 10, 20, 30, 60 min after the isotope
administration) as same as the adults. As the primary
indication, the %13C dose h-1 at 20 min and 30 min com-
bined with the cumulative excretion at 60 min and 120
min not only could cut the breath test time, but were cor-
related with serum TBIL, ALB, PT and Child-Pugh score.
It is shown that 13C-PheBT could reflect compensation of
liver function, especially reflect liver compensatory func-
tion quantitatively. The results were a beneficial comple-
mentary for liver function evaluation. Therefore, PheBT
is a safe, sensitive test and easy to prepare, perform and
analyses, especially in elderly.
Nowadays, the Child-Pugh classification remains the
most widely accepted tool as a measure of disease sever-
ity in liver disease. However, in addition to being safe,
non-invasive, easy to perform, and well correlated with
Table 2: Comparison of liver function and blood test in elderly groups (mean ± SD).
Indicatation Control (n = 38) Chronic 
Hepatitis B 
(n = 30)
Cirrhosis (n = 55)
Child-Pugh A 
(n = 19)
Child-Pugh B 
(n = 28)
Child-Pugh C 
(n = 8)
ALT (IU/L) 23.3 ± 7.3 90.3 ± 34.5a 42.2 ± 17.8 a 52.7 ± 27.8 a 46.3 ± 12.7 a
AST (IU/L) 16.1 ± 5.4 65.4 ± 17.1 a 33.2 ± 11.5 a 43.7 ± 19.8 a, c 51.9 ± 17.1 a, b
GGT (IU/L) 19.6 ± 6.7 23.5 ± 5.8 55.7 ± 33.1 a 59.1 ± 30.1 a 106.0 ± 70.8 a, b, d
ALP (IU/L) 97.3 ± 25.8 101.7 ± 32.2 114.0 ± 58.1 91.8 ± 18.4 c 147.5 ± 63.1 a, c, d
TBIL (μmol/L) 7.9 ± 2.4 9.7 ± 3.4 18.0 ± 5.8 a 22.6 ± 9.4 a, c 64.1 ± 10.5 a, b, d
DBIL (μmol/L) 2.0 ± 0.5 2.3 ± 0.6 7.4 ± 2.7 a 7.3 ± 2.9 a 38.8 ± 2.5 a, b, d
ALB (g/L) 39.9 ± 2.9 39.7 ± 1.9 36.1 ± 2.4 a 30.6 ± 2.1 a, b 25.6 ± 1.1 a, b, d
PT(s) 11.7 ± 1.0 12.1 ± 0.8 14.4 ± 1.5 a 16.7 ± 2.9 a, b 20.9 ± 2.2 a, b, d
HB (g/L) 13.1 ± 1.2 13.2 ± 1.1 11.0 ± 1.1 a 8.5 ± 1.3 a, b 7.9 ± 1.6 a, b
PLT (109/L) 193.3 ± 46.2 175.5 ± 43.2 146.5 ± 41.5 a 91.6 ± 22.5 a, b 90.3 ± 9.9 a, b
Note: ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyltransferase; ALP, alkaline phosphatase; TBIL, serum 
total bilirubin; DBIL, serum direct bilirubin; ALB, serum albumin; PT, prothrombin time; HB, haemoglobin; PLT, platelet count
Compare to control group, a P < 0.01;
Compare with Child-Pugh A: b P < 0.01, c P < 0.05;
Compare between Child-Pugh B and C, d P < 0.05Zhang et al. BMC Geriatrics 2010, 10:23
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the Child-Pugh score, PheBT could provide additional
information in that direct hepatocyte functional capacity
is measured, avoiding any subjectivity in hepatic dysfunc-
tion staging and also avoiding other elements that could
modify the real degree of hepatic damage. The function
tests can provide different information from that
obtained by a liver biopsy, but not such detailed informa-
tion on hepatic disease as that provided by histological
examination. Furthermore, function tests cannot indicate
the extent of inflammation or the degree of fibrosis.
Several factors have prevented widespread adoption of
the 13C-PheBT: it is more expensive and time and labor
consuming than the conventional biochemical tests. But,
it is clear that such tests are superior to the tranditional
Child-Pugh score in predicting survival or life-threaten-
ing complication [28,29]. PheBT is able to discriminate
hepatic functional capacity not only between healthy
individuals and patients with liver disease, but also
between different stages of hepatic dysfunction in adult
and elderly. Our results show that 13C-PheBT can distin-
guish between class A cirrhotics and those with more
advanced disease, but does not appear to be able to dis-
tinguish sufficiently between class B and C cirrhotics.
Well-controlled, prospective trials are needed to clearly
define the role of these quantitative tests in the manage-
ment of patients with liver disease.
Conclusions
In summary, the conclusion of our study is that 13C-
PheBT can be used as a non-invasive assay to evaluate
hepatic function in elderly patients with liver cirrhosis.
The %13C dose h-1 at 20 min, %13C dose h-1 at 30 min and
Table 3: Comparison of %13C dose h-1 curves and %13C cumulative excretion curves after oral administration of L-[1-13C] 
Phenylalanine in elderly groups (mean ± SD).
Time Control (n = 38) Chronic 
Hepatitis B 
(n = 30)
Cirrhosis (n = 55)
Child-Pugh A 
(n = 19)
Child-Pugh B 
(n = 28)
Child-Pugh C 
(n = 8)
13CO2ER t
10 min 8.6 ± 1.4 8.2 ± 1.3 6.2 ± 1.3 a 4.3 ± 1.0 a, c 2.2 ± 0.7 a, c, d
20 min 13.9 ± 1.8 13.1 ± 1.3 8.9 ± 1.7 a 6.2 ± 0.9 a, c 3.7 ± 0.8 a, c, d
30 min 12.3 ± 1.6 11.8 ± 1.6 6.9 ± 1.2 a 5.1 ± 0.6 a, c 4.1 ± 0.3 a, c, e
45 min 6.8 ± 0.8 6.5 ± 0.7 5.4 ± 0.5 a 4.4 ± 0.5 a, c 3.9 ± 0.3 a, c, e
60 min 5.2 ± 0.5 5.1 ± 0.5 4.8 ± 0.5 a 3.9 ± 0.5 a, c 3.5 ± 0.3 a, c, e
90 min 4.5 ± 0.5 4.4 ± 0.5 4.0 ± 0.4 a 3.2 ± 0.5 a, c 2.8 ± 0.4 a, c, e
120 min 3.7 ± 0.5 3.6 ± 0.5 3.1 ± 0.4 a 2.4 ± 0.5 a, c 1.9 ± 0.6 a, c, e
13CCUM t
CUM 10 
min%
1.8 ± 0.3 1.7 ± 0.3 1.3 ± 0.3 a 0.9 ± 0.2 a, c 0.5 ± 0.1 a, c, d
CUM 20 
min%
4.7 ± 0.5 4.4 ± 0.4 3.1 ± 0.6 a 2.2 ± 0.3 a, c 1.2 ± 0.3 a, c, d
CUM 30 
min%
7.2 ± 0.6 6.9 ± 0.4 4.5 ± 0.7 a 3.2 ± 0.3 a, c 2.1 ± 0.3 a, c, d
CUM 45 
min%
8.6 ± 0.7 8.2 ± 0.5 5.7 ± 0.7 a 4.1 ± 0.4 a, c 2.9 ± 0.3 a, c, d
CUM 60 
min%
9.7 ± 0.7 9.3 ± 0.5 6.6 ± 0.8 a 4.9 ± 0.5 a, c 3.6 ± 0.3 a, c, d
CUM 90 
min%
10.6 ± 0.7 10.2 ± 0.5 7.5 ± 0.8 a 5.6 ± 0.5 a, c 4.2 ± 0.4 a, c, d
CUM 120 
min%
11.4 ± 0.8 10.9 ± 0.5 8.1 ± 0.8 a 6.1 ± 0.6 a, c 4.6 ± 0.4 a, c, d
Note: Compare to control group, a P < 0.01, b P < 0.05;
Compare with Child-Pugh A: c P < 0.01;
Compare between Child-Pugh B and C, d P < 0.01, e P < 0.05Zhang et al. BMC Geriatrics 2010, 10:23
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Figure 1 %13C dose h-1 curves (A) and %13C cumulative excretion curves (B) after oral administration of L-[1-13C] Phenylalanine in elderly 
groups. Note: CHB, chronic hepatitis B; CTP, Child-Pugh;
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cumulative excretion at 60 min might be the key value for
determination at a single time-point. The 13C-PheBT is
safe and helpful in distinguishing different stages of
hepatic dysfunction for elderly cirrhosis patients.
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